Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tuberous Sclerosis Complex

The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.

Study Overview

• Status: Completed
• Conditions: Tuberous Sclerosis Complex
• Intervention / Treatment: Drug: NPC-12Y gel; Drug: NPC-12Y placebo gel

Detailed Description

This is a Phase 3, placebo-controlled comparative study of NPC-12Y gel in patients with skin lesions associated with tuberous sclerosis complex. Patients who meet all entry criteria for this study will apply NPC-12Y gel or placebo twice a day for 12 weeks. After the double-blind evaluation period, all patients will apply NPC-12Y gel twice a day for 52 weeks. Approximately 40 eligible patients will be enrolled

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Niigata, Japan
    • National Hospital Organization Nishi-Niigata Chuo Hospital
  • Aichi
    • Toyoake, Aichi, Japan
      • Fujita Health University Hospital
  • Gunma
    • Maebashi, Gunma, Japan
      • Gunma University Hospital
  • Osaka
    • Suita, Osaka, Japan
      • Osaka University Hospital
  • Shizuoka
    • Hamamatsu, Shizuoka, Japan
      • Seirei Hamamatsu General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 months and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female patients 3 years old or greater at the time of informed consent
2. Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012)
3. Patients with three or more reddish papules of angiofibroma ( >= 2 mm in diameter) on the face at screening tests
4. Patients who are not suitable for therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) for angiofibroma, or who do not want therapy with laser or surgery
5. Patients who are being treated with Rapalimus® gel 0.2% (NPC-12G Gel 0.2%) and who are able to and agree to a withdrawal of at least 4 weeks prior to enrollment in this study.
6. Patients who (or whose guardian) give a written informed consent in understanding and willingness after having received enough explanation regarding the study participation.

Exclusion Criteria:

1. Patients who (or whose guardian) are hard to apply the investigational drug topically with keeping compliance
2. Patients who are hard to be taken pictures of their lesions adequately in such cases that they may not follow instruction of stillness
3. Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy
4. Patients with a history or complication of allergy to the component of the investigational drug (sirolimus)
5. Patients who have any infectious disease, cardiac disease, hepatic disease, pulmonary disease, renal disease, hematological disease, or malignant tumor that is considered inappropriate for participation in this clinical study.
6. Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes, dyslipidemia, etc.
7. Patients who have participated in other clinical trial or clinical study, and have taken an investigational or clinical study drug within 6 months before the initial registration
8. Patients who used mTOR inhibitors (oral or injectable) other than everolimus within 4 weeks before the initial registration
9. Female patients who are pregnant, may be pregnant, or are lactating
10. Patients who cannot agree to use appropriate contraception after the date of consent to participate in the clinical study and for the duration of the clinical study (including male patients with a partner of childbearing potential)
11. Patients who have received therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) to the lesion of angiofibroma within 6 months before the initial registration
12. Other patients who are considered by the investigator as unsuitable for participation in the clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NPC-12Y gel; NPC-12Y gel is containing 0.2% Sirolimus	Drug: NPC-12Y gel; NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Placebo Comparator: NPC-12Y placebo gel; Placebo gel matched NPC-12Y gel	Drug: NPC-12Y placebo gel; NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvements in angiofibroma	Improvements comparing with baseline is assessed using photograph by IRC	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvements in angiofibroma, color and size	Improvements comparing with baseline is assessed using photograph by IRC	12 weeks
Index of Facial Angiofibromas (IFA) score	Changes in Index of Facial Angiofibromas (IFA) score assessed by investigators	12 weeks

Collaborators and Investigators

• Sponsor: Nobelpharma

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2022
• Primary Completion (Actual): October 30, 2024
• Study Completion (Actual): October 30, 2024

Study Registration Dates

• First Submitted: August 4, 2022
• First Submitted That Met QC Criteria: August 8, 2022
• First Posted (Actual): August 10, 2022

Study Record Updates

• Last Update Posted (Estimated): November 22, 2024
• Last Update Submitted That Met QC Criteria: November 20, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: Sirolimus; mTOR inhibitor; Tuberous sclerosis complex; Rapalimus gel
• Additional Relevant MeSH Terms: Nervous System Diseases; Pathologic Processes; Neoplasms; Genetic Diseases, Inborn; Neurodegenerative Diseases; Congenital Abnormalities; Heredodegenerative Disorders, Nervous System; Neoplastic Syndromes, Hereditary; Neurocutaneous Syndromes; Hamartoma; Neoplasms, Multiple Primary; Malformations of Cortical Development, Group I; Malformations of Cortical Development; Nervous System Malformations; Sclerosis; Tuberous Sclerosis
• Other Study ID Numbers: NPC-12Y-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No